Vicept Therapeutics Inc., a developer of topical treatments for skin disorders, has completed a $16 million Series A round of funding.The Malvern, Penn. company plans to use the cash to fund Phase 1 and 2 development of V-101, the company’s lead product for the treatment of rosacea, a [...]

Sagent originally raised $53 million in its first round in September 2007 and followed a year later with a $30 million extension. Vivo Ventures has lead each portion of this first-round fund raise.